Accelerate Diagnostics Inc. Faces Delisting from Nasdaq Following Bankruptcy Filing and Compliance Failures
I'm PortAI, I can summarize articles.
Accelerate Diagnostics Inc. is facing delisting from the Nasdaq Stock Market following its voluntary Chapter 11 bankruptcy filing on May 8, 2025. The company received a delisting notice due to public interest concerns and failure to meet minimum bid price and market value requirements. Its stock, consistently below $1.00 per share, will be suspended from trading on May 15, 2025, and is expected to transition to the over-the-counter market as "AXDXQ," though trading is not guaranteed. The company will not appeal the delisting decision.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments